Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294;

React to this article
Latest news on GILEAD SCIENCES, INC.
02:09a GILEAD SCIENCES : Expands hepatitis c alliance with indian partners
01:47a GILEAD SCIENCES : Extends Hepatitis C Generic Licensing Pacts to Include Investi..
01:47a GILEAD SCIENCES : EnvisionRx and Gilead Sciences Ink Deal for Treatment of Hepat..
01:41a GILEAD SCIENCES : Morningstar Recognizes John Martin as 2014 CEO of the Year
01:41a Stockpickers hope to break seven-year skid versus passive funds in 2015
01/28 GILEAD SCIENCES : Announces Executive Promotions
01/28 GILEAD SCIENCES : Change in Directors or Principal Officers (form 8-K)
01/28 GILEAD SCIENCES : expands hepatitis C generic licensing agreements to include in..
01/28 GILEAD SCIENCES : Expands hepatitis c drug licensing pacts with indian firms
01/28 GILEAD SCIENCES : Expands hep c licensing pacts
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes